RefCheck Maintenance Notice

On Monday, December 3, 2018, from 16:00-18:00 EST, RefCheck will be undergoing maintenance. RefCheck is the process where, during copyediting, all references are extracted from the manuscript file, parsed, matched against various databases (eg, PubMed and CrossRef), and automatically corrected. For more information on RefCheck, please visit our Knowledge Base.

Who will be affected?

Citing this Article

Right click to copy or hit: ctrl+c (cmd+c on mac)

Published on 15.12.16 in Vol 5, No 4 (2016): Oct-Dec

This paper is in the following e-collection/theme issue:

Works citing "Development of a Web-Accessible Population Pharmacokinetic Service—Hemophilia (WAPPS-Hemo): Study Protocol"

According to Crossref, the following articles are citing this article (DOI 10.2196/resprot.6558):

(note that this is only a small subset of citations)

  1. Nagao A, Yeung CH, Germini F, Suzuki T. Clinical outcomes in hemophilia A patients undergoing tailoring of prophylaxis based on population-based pharmacokinetic dosing. Thrombosis Research 2019;173:79
    CrossRef
  2. Stoffman J, Andersson NG, Branchford B, Batt K, D’Oiron R, Escuriola Ettingshausen C, Hart D, Jiménez Yuste V, Kavakli K, Mancuso ME, Nogami K, Ramírez C, Wu R. Common themes and challenges in hemophilia care: a multinational perspective. Hematology 2019;24(1):39
    CrossRef
  3. Ragni MV, Croteau SE, Morfini M, Cnossen MH, Iorio A. Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis 2018;16(7):1437
    CrossRef
  4. Croteau SE, Callaghan MU, Davis J, Dunn AL, Guerrera M, Khan O, Neufeld EJ, Raffini LJ, Recht M, Wang M, Iorio A. Focusing in on use of pharmacokinetic profiles in routine hemophilia care. Research and Practice in Thrombosis and Haemostasis 2018;2(3):607
    CrossRef
  5. Castaman G, Linari S. Pharmacokinetic drug evaluation of recombinant factor VIII for the treatment of hemophilia A. Expert Opinion on Drug Metabolism & Toxicology 2018;14(2):143
    CrossRef
  6. Kremer Hovinga ICL, Schutgens REG, van der Valk PR, van Vulpen LFD, Mauser-Bunschoten EP, Fischer K. Continuous infusion of extended half-life factor VIII (efmoroctocog alpha) for surgery in severe haemophilia A. Haemophilia 2018;24(4):e280
    CrossRef
  7. Croteau SE. Evolving Complexity in Hemophilia Management. Pediatric Clinics of North America 2018;65(3):407
    CrossRef
  8. Gupta S, Shapiro AD. Optimizing bleed prevention throughout the lifespan: Womb to Tomb. Haemophilia 2018;24:76
    CrossRef
  9. McEneny-King A, Chelle P, Iorio A, Edginton A. The effect of unmeasurable endogenous plasma factor activity levels on factor VIII dosing in patients with severe hemophilia A. Thrombosis Research 2018;170:53
    CrossRef
  10. Dargaud Y, Delavenne X, Hart D, Meunier S, Mismetti P. Individualized PK-based prophylaxis in severe haemophilia. Haemophilia 2018;24:3
    CrossRef
  11. Iorio A, Edginton AN, Blanchette V, Blatny J, Boban A, Cnossen M, Collins P, Croteau SE, Fischer K, Hart DP, Ito S, Korth-Bradley J, Lethagen S, Lillicrap D, Makris M, Mathôt R, Morfini M, Neufeld EJ, Spears J. Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. Research and Practice in Thrombosis and Haemostasis 2018;2(3):535
    CrossRef
  12. Pasca S, Milan M, Sarolo L, Zanon E. PK-driven prophylaxis versus standard prophylaxis: When a tailored treatment may be a real and achievable cost-saving approach in children with severe hemophilia A. Thrombosis Research 2017;157:58
    CrossRef
  13. Morfini M. The History of Clotting Factor Concentrates Pharmacokinetics. Journal of Clinical Medicine 2017;6(3):35
    CrossRef
  14. Iorio A, Blanchette V, Blatny J, Collins P, Fischer K, Neufeld E. Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis 2017;15(12):2461
    CrossRef
  15. Iorio A, Fischer K, Blanchette V, Rangarajan S, Young G, Morfini M. Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates. Thrombosis and Haemostasis 2017;117(06):1023
    CrossRef
  16. Berntorp E. If you know you will also see: population pharmacokinetics is the way to personalize and optimize prophylaxis in hemophilia. Journal of Thrombosis and Haemostasis 2017;15(6):1103
    CrossRef
  17. Gringeri A, Steinitz-Trost K, Doralt J. Current and future approaches to overcoming the challenges of hemophilia treatment personalization. Expert Opinion on Orphan Drugs 2017;5(7):589
    CrossRef
  18. McEneny-King A, Chelle P, Henrard S, Hermans C, Iorio A, Edginton A. Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis. Pharmaceutics 2017;9(4):47
    CrossRef